Leading pharmaceutical tissue repair We are all living longer but not necessarily living well. With an ageing population and almost all (90%) of us aged 45 years and older set to develop at least one chronic disease in our lifetime, the need for treatments that offer new solutions is essential. At Istesso we are looking at chronic disease differently, focusing on repairing the damage caused by debilitating chronic conditions rather than symptom control. We are leading the field of tissue repair research, a currently untapped area that has the potential to fundamentally change the treatment paradigm for chronic disease and significantly improve patients’ lives. Our unique investigational treatments that repair, rebuild and restore damaged tissue, harness the body’s natural adaptive repair mechanisms, offering people the possibility of living disease free. We believe in a future where chronic diseases can be healed, not just managed, and where the possibility of a disease-free life becomes a reality. Our ambitious, repair-first approach places the body’s innate repair mechanisms at the heart of our approach. We are unapologetic and unafraid to challenge conventional thinking as we execute on our mission to reshape the future by moving us from disease management to disease resolution.
| Website | http://www.istesso.co.uk |
| Revenue | $2 million |
| Employees | 8 (5 on RocketReach) |
| Founded | 2017 |
| Phone | +44 20 7444 0066 |
| Technologies |
JavaScript
,
HTML
,
Google Maps
+7 more
(view full list)
|
| Industry | Biotechnology Research, Manufacturing General, Manufacturing |
| Keywords | Clinical Research, Regenerative Medicine, Drug Development, Disease Reversal, Therapeutic Solutions, Pharmaceutical Research, Cellular Repair, Tissue Regeneration, Functional Restoration, Biomedical Innovation, Advanced Therapies, Health Innovation, Medical Breakthroughs, Symptomatic Relief, Novel Treatments |
| Competitors | Thermo Fisher Scientific, GSK, Merck Group, PPD, Parexel, FUJIFILM Business Innovation Asia Pacific, Charles River Laboratories, Lonza, Covance, Celerion +49 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Istesso employee's phone or email?
The Istesso annual revenue was $2 million in 2026.
Lisa Patel is the CEO and Co-Founder of Istesso.
5 people are employed at Istesso.
The NAICS codes for Istesso are [32541, 325, 3254, 32].
The SIC codes for Istesso are [28, 283].